Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FNGU, a leveraged ETN tracking the FANG+ Index, trades at $28.79, down 0.38% on the day. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, including overbought RSI readings above 80. Recent performance highlights extreme volatility, with a documented 16% single-session drop on June 5, 2026, illustrating the amplified risks of its 3x leverage structure.

The outlook for FNGU is highly speculative, driven entirely by momentum in its underlying tech stocks rather than traditional fundamentals. Investment opportunity exists for aggressive traders betting on continued tech sector strength, but risks are severe, including decay from daily resets and catastrophic losses during market downturns, as recent news demonstrates.

INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.

The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.